Literature DB >> 21544823

A randomized, quadruple crossover single-blind study on immediate action of chewed and unchewed low-dose acetylsalicylic acid tablets in healthy volunteers.

Yoshimichi Sai1, Akiyo Kusaka, Kaori Imanishi, Manami Matsumoto, Rie Takahashi, Natsumi Sugimoto, Junko Sugama, Takako Anada, Hidesaku Asakura, Ken-ichi Miyamoto.   

Abstract

In the initial treatment of acute myocardial infarction, it is important to administer oral low-dose acetylsalicylic acid (ASA) within 10 min of arrival at the hospital. However, ASA is supplied as an enteric-coated tablet or buffered tablet to prevent gastric irritation. Although current guidelines recommended that patients should chew their initial dose of ASA, there is little evidence as to whether this is efficacious. Therefore, we aimed to make a direct comparison of the pharmacokinetics and pharmacodynamics of ASA after ingestion of intact and chewed nonenteric-coated buffered ASA tablet (NBA) and enteric-coated ASA tablet (ECA) in a quadruple crossover study in healthy volunteers. Chewing ECA accelerated t(max) of ASA absorption, which became equivalent to that after ingestion of intact or chewed NBA. A significant decrease in serum thromboxane B(2) was observed 20 min after ingestion of chewed ECA, or intact or chewed NBA, and inhibition of platelet aggregation was also observed within 20 min. Thus, chewing of the ECA appears to result in a similar timing of ASA action to that in the case of chewed or unchewed NBA.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21544823     DOI: 10.1002/jps.22602

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  2 in total

1.  Acetylsalicylic acid in critically ill patients: a cross-sectional and a randomized trial.

Authors:  Christian Schoergenhofer; Eva-Luise Hobl; Michael Schwameis; Georg Gelbenegger; Thomas Staudinger; Gottfried Heinz; Walter S Speidl; Christian Zauner; Birgit Reiter; Irene Lang; Bernd Jilma
Journal:  Eur J Clin Invest       Date:  2017-06-20       Impact factor: 4.686

2.  Randomized, open-label, crossover trial comparing the pharmacokinetic profile of a novel oral aspirin solution and a chewed aspirin tablet.

Authors:  Dan Atar; Sougat Sarkar; Emil Kolev; Carla Mura; Frank Brosstad; Lotte Theodorsen; Geir Ivar Westen; Per Erik Stribolt-Halvorsen
Journal:  Int J Clin Pharmacol Ther       Date:  2022-10       Impact factor: 0.976

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.